With an aim to transform disruptive spine surgery, NuVasive (NASDAQ: NUVA), a leader in spine technology innovation, announced that clinical evaluations have started for its Pulse® platform which recently received CE Mark (Conformitè Europëenne) approval. The Pulse technology, is currently the only technology that can be used in 100% of all spinal procedures and within the operating room (OR). The technology enhances spine surgeries by amalgamating radiation reduction, improving imaging, intraoperative neuromonitoring, surgical navigation, rod bending as well as other spinal alignment tools, all in one platform. Massimo Calafiore, Executive VP, Global Business Units at NuVasive commented on the announcement stating that the, “CE Mark approval and clinical evaluations are key commercialization milestones for the Pulse platform,” and that, “There is a substantial opportunity for enabling technology adoption in spine surgery, and… this next generation of enabling technology has applications that can be utilized in every spine procedure”. Next month, NuVasive will be showcasing the Pulse platform at the Korean American Spine Society and the 37th Annual Meeting of the Section on Disorders of the Spine and Peripheral Nerves.
Read more here.